# A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects

> **NCT03438006** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 3016 (actual)

## Conditions studied

- Cervical Intraepithelial Neoplasia

## Interventions

- **OTHER:** Safety data collection (following routine vaccination)

## Key facts

- **NCT ID:** NCT03438006
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-31
- **Primary completion:** 2020-12-03
- **Final completion:** 2020-12-03
- **Target enrollment:** 3016 (ACTUAL)
- **Last updated:** 2021-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03438006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03438006, "A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03438006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*